Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-3750 in active Crohn's disease
NCT07791888Phase 1Not yet recruiting
- Sponsor
- Rise Therapeutics
- Start
- Nov 2026
- Primary completion
- Dec 2028
01
Overview
Phase 1, randomised, double-blind trial in Crohn's disease comparing R-3750 with Placebo (2 arms). Primary endpoint: Number of Adverse Events at Day 168. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
R-3750
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT07791888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07791888.